文献速递主动脉疾病颈动脉与弓上血管

经胸骨升主动脉为基础的大血管重建术结局

Outcomes of Ascending Aorta-Based Trans-sternal Great Vessel Reconstruction.
PubMed 文献 · Ann Vasc Surg · 2026-02-16

单中心回顾性研究纳入24例接受升主动脉为基础经胸骨大血管重建术(AA-TGVR)的患者,30天死亡率为4.2%,30天卒中和再干预率均为4.2%,晚期死亡率为17.4%;结论认为该术式对闭塞性和非闭塞性大血管病变安全有效,体外循环支持可能有助于脑灌注。

要点

  • AA-TGVR适用于广泛钙化性大血管闭塞病变或0区TEVAR准备。
  • 30天死亡率、卒中和再干预率均较低,但晚期死亡率需关注。
  • 体外循环支持可能作为提供顺行脑灌注的重要辅助手段。

核心结论

  • AA-TGVR对不适合腔内治疗的闭塞性和非闭塞性大血管病变及0区TEVAR仍安全有效。
  • 体外循环支持可能提供术中顺行脑灌注并降低脑缺血风险。

研究设计与样本

  • 单中心回顾性综述,纳入2015年1月1日至2025年8月31日接受AA-TGVR的患者。
  • 排除因A型主动脉夹层行升主动脉修复及大血管再植入的患者。
  • 共纳入24例患者,非闭塞组11例(45.8%),大血管闭塞病变组13例(54.2%)。
  • 平均年龄68.2岁,女性占70.8%。
  • 共施行50例旁路移植血管重建,11例(45.8%)使用体外循环支持作为辅助。

主要发现

  • 30天死亡率为4.2%。
  • 30天卒中率和30天再干预率均为4.2%。
  • 晚期卒中和死亡率分别为4.2%和17.4%。
  • 晚期再干预6例,组间无显著差异。

临床怎么用

  • 对于广泛、钙化性且累及弓部或多支大血管的闭塞病变,可考虑AA-TGVR。
  • 在0区TEVAR术前准备中,AA-TGVR可作为重建大血管血运的方案。
  • 术中可考虑使用体外循环支持提供顺行脑灌注以降低脑缺血风险。

局限性

  • 单中心回顾性研究,样本量小(24例)。
  • 缺乏对照组,远期结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ascending aorta-based trans-sternal great vessel reconstruction (AA-TGVR) is an uncommonly performed procedure in the modern endovascular era. This approach serves an important role for patients with great vessel occlusive disease (GVOD) that is extensive, calcific in nature, and involves the arch or multiple great vessels. It is also indicated in preparation for zone 0 thoracic endovascular repair (TEVAR). The aim of this study is to evaluate our single-center outcomes with AA-TGVR. METHODS: A retrospective review was conducted of patients undergoing AA-TGVR between January 1, 2015 and August 31, 2025. Patients undergoing concomitant ascending aortic repair for type A aortic dissections and great vessel reimplantations were excluded. The primary outcome was 30-day mortality, and secondary outcomes included 30-day stroke, reintervention and late (>30 day) stroke, mortality, and reintervention. RESULTS: A total of 24 patients were included for review. Patients were grouped according to pathology with 11 in the nonocclusive group (45.8%) and 13 in the GVOD group (54.2%). The mean age was 68.2 years and the majority of patients were female at 70.8%. A total of 50 vessel reconstructions via bypass grafting were performed and extracorporeal circulatory support was used as an adjunct in 11 patients (45.8%). The primary outcome of 30-day mortality was 4.2%. The 30-day stroke rate and 30-day reintervention rate were both 4.2%. Late stroke and mortality rate were 4.2% and 17.4%, respectively. There were 6 late reinterventions with no significant difference between groups. CONCLUSION: AA-TGVR remains a safe and effective procedure for both occlusive and nonocclusive disease of the great vessels not amenable to endovascular approaches due to extensive innominate or multivessel disease and for zone 0 TEVAR. ECS may serve as an important adjunct to provide antegrade perfusion to the brain during the procedure and mitigate cerebral ischemia risks.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hlavaty JR, Kathardekar A, Chung JM, et al. Outcomes of Ascending Aorta-Based Trans-sternal Great Vessel Reconstruction. Ann Vasc Surg. 2026. PMID: 41707858. doi:10.1016/j.avsg.2026.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。